Cancer Home > Cometriq and Breastfeeding
The manufacturer of Cometriq (cabozantinib) recommends that women either avoid breastfeeding during treatment or not take the drug. Although no studies have been done to determine if Cometriq passes through breast milk or if it would harm a nursing infant, potentially dangerous side effects are possible, which may pose a risk to a baby whose mother uses the drug while breastfeeding.
Cometriq™ (cabozantinib) is a prescription medication used to treat advanced medullary thyroid cancer. At this time, there is no information available about Cometriq and breastfeeding. The manufacturer recommends that women not breastfeed during treatment.
There have been no studies of Cometriq in breastfeeding mothers. Therefore, it is unknown whether the medication passes through breast milk or if it would harm a nursing child.
While this lack of information is certainly frustrating, it is important to keep in mind that many medicines are not studied in breastfeeding women. This is because doing studies such as these could expose an infant, who would otherwise not receive benefits from the drug, to possible risks.
Cometriq is associated with potentially serious side effects, including severe, life-threatening bleeding problems. Many medicines do pass through breast milk. Therefore, until more information is available, the possibility that a nursing infant could be exposed to Cometriq through breast milk and could develop side effects cannot be ruled out. Because of these risks, the manufacturer recommends that women should either breastfeed or take this drug, but not both.
You should discuss breastfeeding and Cometriq use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.